News - Pharmaceuticals
Medical groups urge NSW Government to halt pharmacist prescribing expansion

Peak medical bodies have mounted a united challenge to the New South Wales Government’s planned expansion of pharmacist prescribing, demanding a pause to the extension into complex chronic conditions until the outcomes of a similar trial underway in Queensland is evaluated.
In a joint letter to NSW Premier Chris Minns, the Australian Medical Association (AMA), Australian Salaried Medical Officers Federation (ASMOF), Royal Australian College of General Practitioners (RACGP), Royal Australasian College of Physicians (RACP) and Royal Australasian College of Surgeons (RACS), warned that the government risks allowing policy ambition to run ahead of clinical evidence.
The organisations have specifically questioned the proposed expansion of pharmacist prescribing into chronic conditions such as hypertension and chronic obstructive pulmonary disease (COPD).
RACGP NSW & ACT Chair Dr Rebekah Hoffman said continuity of care remains one of the strongest predictors of better health outcomes, warning that expanding prescribing models without adequate consideration of existing care relationships undermines a fundamental pillar of general practice.
“General practice is built on long-term relationships that allow a patient’s full medical history, medications and changing health circumstances to be understood over time,” said Dr Hoffman. “The evidence is clear that continuity of care improves outcomes and reduces pressure on hospitals. We should be strengthening those relationships, not introducing models that risk fragmenting care.”
Beyond concerns about diagnostic capabilities and clinical oversight, the organisations have highlighted the potential for conflicts of interest when prescribing and dispensing functions are combined.
AMA (NSW) President Dr Fred Betros questioned the timing and direction of the NSW Government’s announcement, arguing it appeared inconsistent with commitments made by health ministers only days earlier to pursue a nationally consistent approach to prescribing scope of practice.
“The expansion of prescribing into complex chronic conditions should be guided by robust evidence, national consistency and patient safety, not rushed policy decisions,” stated Dr Betros. “Conditions such as hypertension and COPD require accurate diagnosis, ongoing monitoring and continuity of care. These are not one-off presentations that can be safely managed through episodic encounters alone.”
The five organisations are calling on the NSW Government to pause any further expansion of pharmacist prescribing into chronic and complex conditions until an independent evaluation of the Queensland pilot has been completed and publicly released. They also want any subsequent expansion to be underpinned by condition-specific evidence and appropriate safeguards.
The organisations are additionally demanding meaningful consultation with the medical profession and other stakeholders before further scope-of-practice decisions are made, alongside an urgent meeting with Premier Minns to establish a way forward that puts patient safety and clinical evidence ahead of political momentum.
ASMOF NSW President Dr Nicholas Spooner warned that expanding prescribing authority without appropriate clinical safeguards could deepen existing fragmentation across the health system, with potentially serious consequences for patients requiring coordinated care.
“Our members work on the frontline of hospitals and see the consequences when care becomes disconnected,” explained Dr Spooner. “Patients with chronic and complex illness need coordinated care pathways and clear clinical accountability. Any reform must strengthen those systems, not weaken them.”
RACP NSW & ACT Committee Chair Dr Robert Tait said the pace of policy expansion was increasingly outstripping the available evidence, particularly when prescribing responsibilities were being extended into areas requiring sophisticated clinical judgement.
“Managing chronic disease safely depends on understanding diagnostic uncertainty, identifying red flags and coordinating care across multiple providers,” emphasised Dr Tait. “We remain concerned that pharmacist prescribing is being expanded into increasingly complex areas without the level of evidence or evaluation that patients deserve.”
RACS NSW State Committee Chair Dr Danette Wright also called for greater scrutiny before governments make fundamental changes to prescribing arrangements, arguing that the potential consequences extend beyond individual consultations to the broader operation of the healthcare system.
“Healthcare reform must be driven by evidence and patient outcomes,” said Dr Wright. “Before expanding prescribing authority into more complex conditions, governments should ensure there is a clear understanding of the benefits, risks and impacts on the broader health system.”
Despite their strong objections to the proposed expansion, the five organisations stressed that their position should not be interpreted as opposition to multidisciplinary healthcare or the contribution pharmacists make to patient care.
Rather, the central issue was whether expanding prescribing and diagnostic responsibilities without sufficiently established evidence, governance and accountability arrangements would ultimately improve access or introduce new risks into an already complex healthcare landscape.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More